NCT00406094

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Bernstein, Jonathan A., M.D. · Individual
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.

Detailed description

Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.

Conditions

• Rhinitis

Interventions

Type	Name	Description
DRUG	montelukast	10mg
DRUG	placebo	placebo

Timeline

• Start date: 2006-11-01
• Primary completion: 2009-12-01
• Completion: 2009-12-01
• First posted: 2006-12-04
• Last updated: 2009-01-16

Locations

1 site across 1 country: United States